论文部分内容阅读
目的探讨内源性一氧化氮（ＮＯ）在肺癌发生发展中的作用。方法对４６例肺癌患者及健康对照组均用化学显色法测定血清ＮＯ，同时对肺癌患者分组比较及治疗前后比较，并对结核性及恶性胸液患者用上述方法测定胸液中ＮＯ。结果肺癌组血清ＮＯ显著高于正常对照组，Ｐ＜００５；Ⅰ期肺癌患者血清ＮＯ显著高于Ⅱ期患者，Ⅰ、Ⅱ期患者血浆ＮＯ显著高于Ⅲ期患者，Ｐ＜００５；治疗后肺癌患者血浆及胸液ＮＯ水平明显降低，Ｐ＜００５；鳞癌组血清ＮＯ显著高于腺癌组，Ｐ＜００５；恶性胸液患者胸液中ＮＯ与结核性胸液ＮＯ无显著差异，Ｐ＞００５，无统计学意义。结论内源性ＮＯ在抑制和杀伤肺癌细胞方面起重要作用，应用药物诱导产生内源性ＮＯ可为今后治疗肺癌提供一种新的手段。
Objective To investigate the role of endogenous nitric oxide (NO) in the development of lung cancer. Methods Forty-six patients with lung cancer and healthy controls were examined for serum NO by chemical chromogenic assay. Patients were also compared for lung cancer before and after treatment. The levels of NO in pleural fluid were measured in patients with tuberculous and malignant pleural effusion. Results Serum NO in lung cancer group was significantly higher than that in normal control group (P<005). Serum NO in patients with stage I lung cancer was significantly higher than that in stage II patients. Plasma NO was significantly higher in stage I and II patients than in stage III patients, P<005 After treatment, NO levels in plasma and pleural fluid of lung cancer patients decreased significantly, P<0.05; serum NO in squamous cell carcinoma group was significantly higher than that in adenocarcinoma group, P<005; NO and tuberculous chest in pleural fluid of patients with malignant pleural effusion There was no significant difference in liquid NO, P>005, no statistical significance. Conclusion Endogenous NO plays an important role in inhibiting and killing lung cancer cells. The application of drugs to induce endogenous NO may provide a new method for the treatment of lung cancer in the future.